These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15536079)

  • 1. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55).
    Harris CL; Abbott RJ; Smith RA; Morgan BP; Lea SM
    J Biol Chem; 2005 Jan; 280(4):2569-78. PubMed ID: 15536079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
    Harris CL; Pettigrew DM; Lea SM; Morgan BP
    J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
    Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
    Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.
    Hourcade DE; Mitchell L; Kuttner-Kondo LA; Atkinson JP; Medof ME
    J Biol Chem; 2002 Jan; 277(2):1107-12. PubMed ID: 11694537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
    Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
    J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
    Brodbeck WG; Mold C; Atkinson JP; Medof ME
    J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.
    Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
    J Immunol; 2009 Dec; 183(11):7347-51. PubMed ID: 19890040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decay acceleration of the complement alternative pathway C3 convertase.
    Hourcade DE; Mitchell LM; Medof ME
    Immunopharmacology; 1999 May; 42(1-3):167-73. PubMed ID: 10408377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and function of recombinant cobra venom factor.
    Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
    J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C; Walter EI; Medof ME
    J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.
    Pangburn MK
    Immunology; 1990 Dec; 71(4):598-600. PubMed ID: 1703989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
    Hourcade DE
    J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional role of the noncatalytic subunit of complement C5 convertase.
    Rawal N; Pangburn MK
    J Immunol; 2000 Feb; 164(3):1379-85. PubMed ID: 10640753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the active sites in decay-accelerating factor.
    Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
    J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase.
    Ponnuraj K; Xu Y; Macon K; Moore D; Volanakis JE; Narayana SV
    Mol Cell; 2004 Apr; 14(1):17-28. PubMed ID: 15068800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.